{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:43:56Z","timestamp":1767134636854,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd003347.pub2","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"record-id":"30949"},{"DOI":"10.1002\/14651858.cd003347","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"record-id":"30950"},{"DOI":"10.1002\/14651858.cd003347.pub2","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000}}],"reference-count":75,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003347.pub3","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T06:40:31Z","timestamp":1490337631000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radioisotopes for metastatic bone pain"],"prefix":"10.1002","author":[{"given":"Marta","family":"Roqu\u00e9 i Figuls","sequence":"first","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 171 Edifici Casa de Convalesc\u00e8ncia Barcelona Catalunya Spain 08041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9","family":"Martinez-Zapata","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 171 Edifici Casa de Convalesc\u00e8ncia Barcelona Catalunya Spain 08041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Scott-Brown","sequence":"additional","affiliation":[{"name":"Gray Institute for Radiation Oncology & Biology; Radiobiology Research Institute Churchill Hospital Oxford UK OX3 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Alonso-Coello","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute Sant Pau (IIB Sant Pau); Iberoamerican Cochrane Centre; CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Spain Sant Antoni Maria Claret 171 - Edifici Casa de Convalescencia Barcelona Catalunya Spain 08041"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD003347.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MNM.0b013e32805b72a0","article-title":"89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma","volume":"28","author":"Baczyk","year":"2007","journal-title":"Nuclear Medicine Communications"},{"issue":"7-8","key":"10.1002\/14651858.CD003347.pub3-BIB2|cit2","first-page":"349","article-title":"Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma","volume":"14","author":"Buchali","year":"1988","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1002\/14651858.CD003347.pub3-BIB3|cit3","article-title":"Efficacy and toxicity of samarium-153-EDTMP locally produced in the treatment of painful skeletal metastases","volume-title":"IAEA-TECDOC-1228","author":"Olea","year":"1999"},{"key":"10.1002\/14651858.CD003347.pub3-BIB4|cit4","first-page":"146","article-title":"Efficacy and toxicity of 153Sm EDTMP in the palliative treatment of painful skeleton metastases: results of an IAEA international multicenter study","volume":"51","author":"Olea","year":"2000","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1002\/14651858.CD003347.pub3-BIB5|cit5","article-title":"Random comparison study of the clinical response to 153SM-EDTMP 1.0 mg mCi\/Kg and 1.5 mg mCi\/Kg","volume-title":"IAEA-TECDOC-1228","author":"Pan","year":"1999"},{"issue":"1","key":"10.1002\/14651858.CD003347.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s002590050351","article-title":"Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China","volume":"26","author":"Tian","year":"1999","journal-title":"European Journal of Nuclear Medicine"},{"issue":"9","key":"10.1002\/14651858.CD003347.pub3-BIB7|cit7","first-page":"1150","article-title":"The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186) Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study","volume":"43","author":"Han","year":"2002","journal-title":"Journal of Nuclear Medicine"},{"issue":"8","key":"10.1002\/14651858.CD003347.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":"A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone","volume":"27","author":"Lewington","year":"1991","journal-title":"European Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD003347.pub3-BIB9|cit9","first-page":"1877","article-title":"Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo","volume":"32","author":"Maxon","year":"1991","journal-title":"Journal of Nuclear Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003347.pub3-BIB10|cit10","first-page":"256","article-title":"Relative efficacy of 32P and 89Sr in palliation in skeletal metastases","volume":"40","author":"Nair","year":"1999","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1002\/14651858.CD003347.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncology"},{"issue":"16","key":"10.1002\/14651858.CD003347.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.2003.12.060","article-title":"Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate","volume":"21","author":"Palmedo","year":"2003","journal-title":"Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology"},{"issue":"3 Suppl 2","key":"10.1002\/14651858.CD003347.pub3-BIB14|cit13","first-page":"38","article-title":"Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial","volume":"20","author":"Porter","year":"1993","journal-title":"Seminars in Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003347.pub3-BIB13|cit14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized Phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"International Journal of Radiation, Oncology, Biology and Physics"},{"issue":"10","key":"10.1002\/14651858.CD003347.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0959-8049(97)00155-X","article-title":"A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases","volume":"33","author":"Resche","year":"1997","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003347.pub3-BIB16|cit16","series-title":"Proceedings of the Annual Meeting American Society of Clinical Oncology","first-page":"A1654","article-title":"Efficacy and safety of 153Sm-EDTMP in alleviating the pain of bone metastases in patients with prostate carcinoma (Meeting abstract)","author":"Quick","year":"1996"},{"issue":"4","key":"10.1002\/14651858.CD003347.pub3-BIB17|cit17","first-page":"321","article-title":"A double blind placebo controlled study of 153Samarium-EDTMP for palliation of bone pain in patients with hormone refractory prostate cancer (abstract)","volume":"157","author":"Sartor","year":"1997","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD003347.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"issue":"2","key":"10.1002\/14651858.CD003347.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1010658522847","article-title":"Metastatic bone pain palliation with 89-Sr and 186-re-HEDP in breast cancer patients","volume":"66","author":"Sciuto","journal-title":"Breast Cancer Research and Treatment"},{"issue":"4","key":"10.1002\/14651858.CD003347.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.1998.16.4.1574","article-title":"Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial","volume":"16","author":"Serafin","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD003347.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0360-3016(03)00274-8","article-title":"Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study","volume":"56","author":"Smeland","year":"2003","journal-title":"International Journal of Radiation, Oncology, Biology and Physics"},{"issue":"10","key":"10.1002\/14651858.CD003347.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/BF00181067","article-title":"Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer","volume":"21","author":"Klerk","year":"1994","journal-title":"Nuclear Medicine and Molecular Imaging"},{"issue":"4","key":"10.1002\/14651858.CD003347.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1440-1673.1999.00716.x","article-title":"Strontium and samarium therapy for bone metastases from prostate carcinoma","volume":"43","author":"Dickie","year":"1999","journal-title":"Australasian-Radiology"},{"issue":"2","key":"10.1002\/14651858.CD003347.pub3-BIB24|cit24","first-page":"48","article-title":"[The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer]. [German]","volume":"31","author":"Haesner","year":"1992","journal-title":"Nuklearmedizin"},{"issue":"6","key":"10.1002\/14651858.CD003347.pub3-BIB25|cit25","first-page":"146","article-title":"Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases]. [German]","volume":"39","author":"Liepe","journal-title":"Nuclear-Medizin"},{"issue":"8","key":"10.1002\/14651858.CD003347.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MNM.0b013e32825a6adc","article-title":"A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases","volume":"28","author":"Liepe","year":"2007","journal-title":"Nuclear Medicine Communications"},{"issue":"6","key":"10.1002\/14651858.CD003347.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/104990910502200613","article-title":"Systemic radionuclide therapy in pain palliation","volume":"22","author":"Liepe","year":"2005","journal-title":"The American Journal of Hospice & Palliative Care"},{"issue":"11","key":"10.1002\/14651858.CD003347.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/cncr.24286","article-title":"Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma","volume":"115","author":"Loeb","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD003347.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0090-4295(97)00326-9","article-title":"Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and\/or external radiotherapy","volume":"50","author":"Malmberg","year":"1997","journal-title":"Urology"},{"issue":"SUPPL. 1","key":"10.1002\/14651858.CD003347.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000475428","article-title":"A retrospective analysis of the cost effectiveness of treatment with metastron in patients with prostate cancer metastatic to bone","volume":"26","author":"McEwan","year":"1994","journal-title":"European-Urology"},{"issue":"15","key":"10.1002\/14651858.CD003347.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.2008.20.4164","article-title":"Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer","volume":"27","author":"Morris","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003347.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpainsymman.2004.07.008","article-title":"Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study","volume":"29","author":"Nilsson","year":"2005","journal-title":"Journal of Pain and Symptom Management"},{"issue":"5","key":"10.1002\/14651858.CD003347.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0302-2838(03)00364-6","article-title":"Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group","volume":"44","author":"Oosterhof","year":"2003","journal-title":"European Urology"},{"issue":"2-3","key":"10.1002\/14651858.CD003347.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"406 Suppl","DOI":"10.1016\/S1359-6349(09)71381-3","article-title":"A double blind, randomised, dose finding, phase II, multicentre study of radium-223 for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC): EudraCT number: 2005-003680-22","volume":"7","author":"Parker","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD003347.pub3-BIB35|cit35","article-title":"Initial feasibility and safety results from a phase II\/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) +\/- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747","volume":"28","author":"Porfiri","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003347.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","article-title":"A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer","volume":"31","author":"Quilty","year":"1994","journal-title":"Radiotherapy and Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003347.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bone.2005.12.004","article-title":"Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases","volume":"39","author":"Storto","year":"2006","journal-title":"Bone"},{"issue":"9253","key":"10.1002\/14651858.CD003347.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(00)03639-4","article-title":"Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial","volume":"357","author":"Tu","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD003347.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000069120","article-title":"A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer","volume":"12","author":"Wang","year":"2003","journal-title":"Medical Principles & Practice"},{"issue":"5","key":"10.1002\/14651858.CD003347.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/cbr.2008.0600","article-title":"Management of metastatic bone pain with repeated doses of rhenium 186-hedp in patients under therapy with zoledronic acid: A safe and additively effective practice","volume":"24","author":"Zafeirakis","year":"2009","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"},{"issue":"5","key":"10.1002\/14651858.CD003347.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/108497803770418265","article-title":"Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients","volume":"18","author":"Zhang","year":"2003","journal-title":"Cancer Biotherapy & Radiopharmaceuticals"},{"issue":"11","key":"10.1002\/14651858.CD003347.pub3-BIB42|cit42","first-page":"23","article-title":"Combining Strontium-89 with 99Tc-MDP for treatment of: Painful bone metastases of prostate cancer","volume":"23","author":"Ma","journal-title":"Chinese Journal of Andrology"},{"key":"10.1002\/14651858.CD003347.pub3-BIB43|cit43","unstructured":"A double-blind, dose-response phase II, multicentre study of Radium-223 (Alpharadin TM) for the palliation of painful bone metastases in hormone refractory prostate cancer patients. Ongoing study"},{"key":"10.1002\/14651858.CD003347.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2106\/00004623-199706000-00018","article-title":"Treatment of metastatic adenocarcinoma of the pelvis and the extremities","volume":"79","author":"Aaron","year":"1997","journal-title":"The Journal of Bone and Joint Surgery"},{"key":"10.1002\/14651858.CD003347.pub3-BIB45|cit45","volume-title":"Clinical Practice Guidelines for the management of locally advanced and metastasic prostate cance","year":"2009"},{"issue":"10","key":"10.1002\/14651858.CD003347.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s00259-008-0841-y","article-title":"EANM procedure guideline for treatment of refractory metastatic bone pain","volume":"35","author":"Bodei","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1002\/14651858.CD003347.pub3-BIB47|cit47","unstructured":"Brundage MD Crook JM Lukka H and the Genitourinary Cancer Disease Site Group Use of Strontium-89 in patients with endocrine-refractory carcinoma of the prostate metastatic to bone http:\/\/hiru.mcmaster.ca\/ccopgi\/guidelines\/gen\/cpg3_6f.html"},{"issue":"11","key":"10.1002\/14651858.CD003347.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","article-title":"Palliative radiotherapy trials for bone metastases: a systematic review","volume":"25","author":"Chow","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003347.pub3-BIB49|cit49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD003347.pub3-BIB50|cit50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(05)70206-0","article-title":"Radioisotopes for the palliation of metastatic bone cancer: a systematic review","volume":"6","author":"Finlay","year":"2005","journal-title":"Lancet Oncology"},{"issue":"10","key":"10.1002\/14651858.CD003347.pub3-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"7650","key":"10.1002\/14651858.CD003347.pub3-BIB52|cit52","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003347.pub3-BIB53|cit53","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD003347.pub3-BIB54|cit54","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch16","article-title":"Chapter 16: Special topics in statistics","volume-title":"Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009)","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD003347.pub3-BIB55|cit55","article-title":"Criteria for palliation of bone metastases - Clinical applications","volume-title":"Criteria for palliation of bone metastases - clinical applications. IAEA-TECDOC-1549","author":"IAEA","year":"2007"},{"issue":"28","key":"10.1002\/14651858.CD003347.pub3-BIB56|cit56","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003347.pub3-BIB57|cit57","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003223.pub2","article-title":"Calcitonin for metastatic bone pain","author":"Martinez-Zapata","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003347.pub3-BIB58|cit58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/cbr.1998.13.413","article-title":"Palliative therapy with bone seeking radiopharmaceuticals","volume":"13","author":"McEwan","year":"1998","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"},{"issue":"3","key":"10.1002\/14651858.CD003347.pub3-BIB59|cit59","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001793","article-title":"Radiotherapy for the palliation of painful bone metastases","author":"McQuay","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003347.pub3-BIB60|cit60","first-page":"361","article-title":"Systemic bone-seeking Radionuclides for palliation of painful osseous metastases: current concepts","volume":"48","author":"Mertens","year":"1998","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD003347.pub3-BIB61|cit61","unstructured":"Medicare Services Advisory Committee Samarium153-lexidronam for bone pain due to skeletal metastases. MSAC application 1016 http:\/\/www.health.gov.au\/haf\/msac."},{"key":"10.1002\/14651858.CD003347.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1991.9.3.509","article-title":"Bone metastatic: pathophysiology and management policy","volume":"9","author":"Nelson","year":"1991","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD003347.pub3-BIB63|cit63","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474.pub2","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003347.pub3-BIB64|cit64","unstructured":"Therapeutic Radiopharmaceutical Guidelines Group Radiopharmaceuticals for the palliation of painful bone metastases. Practice Guidelines Report #14-1 Toronto Cancer Care Ontario"},{"issue":"1","key":"10.1002\/14651858.CD003347.pub3-BIB65|cit65","first-page":"15","article-title":"Pathophysiology of bone cancer pain","volume":"3","author":"Sabino","year":"2005","journal-title":"The Journal of Supportive Oncology"},{"key":"10.1002\/14651858.CD003347.pub3-BIB66|cit66","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.9 (updated September 2009)","author":"Sch\u00fcnemann","year":"2008"},{"issue":"1","key":"10.1002\/14651858.CD003347.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2106\/00004623-200201000-00008","article-title":"Pathologic fracture in osteosarcoma: prognostic importance and treatment implications","volume":"84-A","author":"Scully","year":"2002","journal-title":"Journal of Bone and Joint Surgery. American volume"},{"issue":"4","key":"10.1002\/14651858.CD003347.pub3-BIB68|cit68","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005247.pub2","article-title":"Chemotherapy for hormone-refractory prostate cancer","author":"Shelley","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003347.pub3-BIB69|cit69","unstructured":"Silberstein E Buscombe J McEwan A Taylor A Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases. version 3.0 Web source"},{"key":"10.1002\/14651858.CD003347.pub3-BIB70|cit70","first-page":"[Epub ahead of","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"Nov 8","author":"Stopeck","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD003347.pub3-BIB71|cit71","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004721","article-title":"Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy","author":"Sze","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD003347.pub3-BIB72|cit72","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02712817","article-title":"Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases","volume":"7","author":"Latr\u00e1s","journal-title":"Clinical Translational Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003347.pub3-BIB73|cit73","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002068","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases","author":"Wong","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003347.pub3-BIB74|cit74","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006250","article-title":"Bisphosphonates for advanced prostate cancer","author":"Yuen","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003347.pub3-BIB75|cit75","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003347","article-title":"Radioisotopes for metastatic bone pain","author":"Roqu\u00e9","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003347.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:19:23Z","timestamp":1628529563000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003347.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":75,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003347.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]}}}